Compare ENOV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | HRMY |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2008 | 2020 |
| Metric | ENOV | HRMY |
|---|---|---|
| Price | $27.24 | $37.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $49.14 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 854.1K | 772.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $2,233,266,000.00 | $825,944,000.00 |
| Revenue This Year | $9.27 | $23.11 |
| Revenue Next Year | $4.56 | $16.15 |
| P/E Ratio | ★ N/A | $12.24 |
| Revenue Growth | 11.57 | ★ 21.13 |
| 52 Week Low | $25.47 | $25.52 |
| 52 Week High | $49.38 | $40.93 |
| Indicator | ENOV | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 57.18 |
| Support Level | $25.52 | $38.12 |
| Resistance Level | $28.02 | $40.87 |
| Average True Range (ATR) | 1.28 | 1.35 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 31.79 | 42.28 |
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.